Company profile
Rest Ez Inc.
OTC: RTEZ · Healthcare · Medical - Pharmaceuticals
#1161 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
——FH —DQ 13GM —SS 35
v0.1 · 25/100 weight · pillars only
↑ market scale, disclosure history · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$7.9k
Employees
5
as of 2026-08-01
Market cap
$1.9B
as of 2026-08-01
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$7.9k-$7.9k2025
Operating income-$7.9k-$7.9k2025
Total assets$300$3002025
Equity$300$3002025
Revenue trend
FY2022 – FY2025 · USD
FY22
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Rest Ez Inc.’s revenue?
Rest Ez Inc. booked $0 in FY2025 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Viking Therapeutics, Inc.69BAmylyx Pharmaceuticals, Inc.51DSELLAS Life Sciences Group, Inc.50DKardigan, Inc.——Cullinan Therapeutics, Inc.50DDesign Therapeutics, Inc.55CNeighbors
Salt Lake →Key facts
CEODylan Carson
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersRiverton, UT
ExchangeOTC: RTEZ
Employees5
IPO date2025-06-02
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.